Adaptive Biotechnologies CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Viking Global Investors filed an amended Schedule 13G to reflect the removal of David C. Ott as a reporting person.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Adaptive Biotechnologies Corp. following an internal realignment.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Adaptive Biotechnologies Stake to 7.9%
BlackRock, Inc. reports a 7.9% beneficial ownership stake in Adaptive Biotechnologies Corp, holding 11,992,448 common shares.
NASDAQ
Rubric Capital Management LP and David Rosen have reported a 4.12% beneficial ownership stake in Adaptive Biotechnologies Corporation as of June 30, 2025, indicating a passive investment position.
NASDAQ
SCHEDULE 13G/A: ARK Investment Management and Catherine Wood Disclose 2.9% Stake in Adaptive Biotechnologies
ARK Investment Management LLC and its CEO Catherine D. Wood have filed an amended Schedule 13G, disclosing a beneficial ownership of 2.9% in Adaptive Biotechnologies Corporation's common stock as of May 31, 2025.
NASDAQ
SCHEDULE 13G: ARK Investment Management and Catherine Wood Disclose 5.2% Stake in Adaptive Biotechnologies
ARK Investment Management LLC and its CEO, Catherine D. Wood, have jointly disclosed a beneficial ownership of 5.2% in Adaptive Biotechnologies Corporation, totaling 7,732,570 shares of common stock.
NASDAQ
ARK Investment Management LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 3.99% in Adaptive Biotechnologies Corporation as of April 30, 2025.
NASDAQ
BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G, disclosing a 6.7% passive beneficial ownership stake in Adaptive Biotechnologies Corp as of March 31, 2025.
NASDAQ
ARK Investment Management LLC has filed an amended Schedule 13G, revealing a 6.39% beneficial ownership stake in Adaptive Biotechnologies Corp as of December 31, 2024.
NASDAQ
Nikko Asset Management Americas, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 4.63% of Adaptive Biotechnologies Corp.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Sumitomo Mitsui Trust Group and Nikko Asset Management Amend Adaptive Biotechnologies Stake to 4.6%
Sumitomo Mitsui Trust Group, Inc. and Nikko Asset Management Co., Ltd. have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 4.6% in Adaptive Biotechnologies Corporation as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Millennium Entities Reduce Stake in Adaptive Biotechnologies, Beneficial Ownership Falls Below 5%
Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, indicating a reduction in their beneficial ownership of Adaptive Biotechnologies Corporation's common stock, with individual holdings now below 5% as of December 31, 2024.